Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine

Figure 2

Selection for EPISSAY system. Flow cytometric assessment and western blot of the parental (A) RFP-TMnfsB expressing clone T1 and (B) untransduced MCF10A cells. The densitometry on western blots was quantified using ImageJ program. (C) Flow cytometric assessment of the CB1954-resistant clones generated from T1. Top panel: low fluorescent clones LT1, LT2 and LT3. Bottom panel: high fluorescent clones HT1, HT2, HT3 and HT4. Treatments were: decitabine 1, 10, 50 μM or zebularine 50, 100, 500 μM for 72 hours in triplicate in <1% v/v DMSO. Red-fluorescent reading is the gated geometric mean value of FL3-H. Note the different y axis scales for each panel. Unpaired two-tailed t-test, data expressed as mean ± SEM. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.

Back to article page